IntroductionLung cancer is the leading global cause of cancer-related deaths. Studies
suggest that EGFR-dependent signaling pathways in lung cancer may predispose patients …

The emergence of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
caused a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). Although …

Background Despite increases in PFS in EGFR-positive lung cancer patients due to EGFR
TKIs, patients eventually develop resistance to these drugs. Project PRIORITY (Patient …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S176-S178 tlcr. amegroups. com benefit was shown in EGFR mutation-positive …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …

Prior to November 2023, the main first-line therapy utilized for the treatment of patients with
EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase 3 …

The clinical development of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) for treatment of non-small cell lung cancer (NSCLC) is a major breakthrough in …

The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited
by the inevitable development of treatment resistance. Two reports in this issue of Cancer …

9086 Background: Osimertinib (osi) demonstrated improved progression-free survival (PFS)
over erlotinib as initial treatment (trmt) for EGFR-mutant (EGFR+) lung cancers. The addition …

Interstitial lung disease (ILD) refers to a diverse range of pulmonary fibrotic disorders and
may be hard to accurately diagnose, as distinguishing it from other pulmonary diseases can …